This trial is evaluating whether Anetumab Ravtansine will improve 1 primary outcome and 1 secondary outcome in patients with Adenocarcinoma. Measurement will happen over the course of Up to 100 days post treatment.
This trial requires 74 total participants across 3 different treatment groups
This trial involves 3 different treatments. Anetumab Ravtansine is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Treatment can vary due to a number of factors, including race, age, treatment type, and disease stage. Patients over age 75 should seek attention regarding the possible detrimental effects of their medications. Patients should also seek medical attention when new symptoms of disease or problems are noticed. In most cases, it is recommended that adenocarcinoma patients seek treatment at an internal medicine or oncology department. Local therapy can sometimes be carried out, depending on the stage of carcinoma, age, and the health status of the patient.
About 75,000,000 men are diagnosed with prostate cancer each year in the United States. The number of men diagnosed with lung cancer, colorectal cancer, and pancreatic cancer are also increasing. The United States spends an annual average of $10.2 billion on health care (excluding Medicare), and Medicare spending per capita is 9.7 percent of federal spending, making this a major source of health care spending in the United States. It is clear that the demand for medical services is outrunning health system resources and that the current system of providing health care to an ever-increasing number of people will have serious consequences that we must understand to anticipate and overcome.
Adenocarcinoma encompasses tumors that include the word "adenocarcinoma" in the name. Most adenocarcinomas begin in a non-cancerous (benign) state and progress to carcinoma as they spread through the surrounding tissues to nearby areas. However, some cancers may begin in a cancerous state and remain stable (malignant) or progress (recurrent) until dying of another cause. Adenocarcinomas include many different tumors. If you hear of a tumor that has cancer in the name or if you see a solid tumor, then find out if the surgeon said the tumors appeared to be adenocarcinoma because they all have cancerous qualities.
This report provides a comprehensive review of the presenting features of adenocarcinoma, the clinical signs and other abnormal clinical findings (such as anemia, bone pain and ocular abnormalities) that may be found when patients are admitted to the hospital with a suspicion of acute cancer or an unknown primary. This summary of clinical signs and other findings can be useful for educating the public and nurses when interpreting the clinical history and findings.
Cancers of mucosal surfaces do not always require therapy for curing. Prostate cancer is an exception. With aggressive, adjuvant therapy, the incidence of cure is over 95% among localized, high-grade, stage T1-T3 cancers.
These data support both the anti-MMA2 and anti-CD20 mechanisms of action of anetumab and support further clinical exploration of anetumab as a potential immune checkpoint inhibitor for cancers which overexpress CD20+ B cells or which express high amounts of MAM1 protein.
The most common side effects with anetumab ravtansine were fatigue and rash (22 and 24%, respectively). All side effects were non-serious and manageable, and manageable discontinuation rates were >88%.
Anetumab ravtansine substantially improved quality of life and resulted in better tolerability and compliance during the Phase III trial than both chemotherapy and observation in patients with metastatic adenocarcinoma of the peritoneum.
the anetumab ravtansine demonstrates substantial antitumor activity, with good safety and tolerability profiles with preliminary evidence of significant clinical antifibrotic activity. Clinical trials are ongoing globally.
Anetumab ravtansine significantly improved OS in this second phase II trial versus a placebo in patients with metastatic metastatic colorectal cancer. The data demonstrate that the investigational combination is more effective than standard of care. Patients with a PD-1 or PD-L1 mutation (or both) were shown to have a partial response to anetumab ravtansine and improved OS relative to the patients not expressing any of these biomarkers.
Tobacco tobacco was the most common presenting risk factor for AADC. The incidence of squamous cell carcinoma was also significantly increased. Other factors could be involved, in addition to the effect of tobacco alone.